ESSA Pharma Inc.

NasdaqCM:EPIX Stock Report

Market Cap: US$75.0m

ESSA Pharma Future Growth

Future criteria checks 3/6

ESSA Pharma is forecast to grow earnings and revenue by 45.9% and 44.4% per annum respectively while EPS is expected to grow by 46.5% per annum.

Key information

45.9%

Earnings growth rate

46.5%

EPS growth rate

Biotechs earnings growth27.6%
Revenue growth rate44.4%
Future return on equityn/a
Analyst coverage

Low

Last updated23 Dec 2024

Recent future growth updates

Recent updates

Companies Like ESSA Pharma (NASDAQ:EPIX) Are In A Position To Invest In Growth

Aug 21
Companies Like ESSA Pharma (NASDAQ:EPIX) Are In A Position To Invest In Growth

We're Not Very Worried About ESSA Pharma's (NASDAQ:EPIX) Cash Burn Rate

Feb 18
We're Not Very Worried About ESSA Pharma's (NASDAQ:EPIX) Cash Burn Rate

ESSA Pharma (NASDAQ:EPIX) Is In A Good Position To Deliver On Growth Plans

Aug 16
ESSA Pharma (NASDAQ:EPIX) Is In A Good Position To Deliver On Growth Plans

Estimating The Fair Value Of ESSA Pharma Inc. (NASDAQ:EPIX)

Jan 25
Estimating The Fair Value Of ESSA Pharma Inc. (NASDAQ:EPIX)

We're Hopeful That ESSA Pharma (NASDAQ:EPIX) Will Use Its Cash Wisely

Dec 15
We're Hopeful That ESSA Pharma (NASDAQ:EPIX) Will Use Its Cash Wisely

ESSA Pharma: Update Including Clinical Collaboration Agreement With Janssen

Feb 02

ESSA Pharma and Janssen to test combo treatments in prostate cancer setting

Jan 13

ESSA Pharma EPS beats by $0.02

Dec 15

Earnings and Revenue Growth Forecasts

NasdaqCM:EPIX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/20274225-132N/A4
9/30/20264-17-94N/A5
9/30/2025N/A-23-63N/A5
9/30/2024N/A-29-23-23N/A
6/30/2024N/A-28-24-24N/A
3/31/2024N/A-28-23-23N/A
12/31/2023N/A-26-22-22N/A
9/30/2023N/A-27-20-20N/A
6/30/2023N/A-27-23-23N/A
3/31/2023N/A-29-24-24N/A
12/31/2022N/A-33-27-27N/A
9/30/2022N/A-35-28-28N/A
6/30/2022N/A-37-28-28N/A
3/31/2022N/A-37-28-28N/A
12/31/2021N/A-39-27-27N/A
9/30/2021N/A-37-25-25N/A
6/30/2021N/A-33-22-22N/A
3/31/2021N/A-29-19-19N/A
12/31/2020N/A-25-18-18N/A
9/30/2020N/A-23-17-17N/A
6/30/2020N/A-22-18-18N/A
3/31/2020N/A-21-17-17N/A
12/31/2019N/A-15-14-14N/A
9/30/2019N/A-13-12-12N/A
6/30/2019N/A-12-9-9N/A
3/31/2019N/A-11-10-10N/A
12/31/2018N/A-12-10-10N/A
9/30/2018N/A-12-10-10N/A
6/30/2018N/A-11N/A-11N/A
3/31/2018N/A-5N/A-13N/A
12/31/2017N/A-8N/A-13N/A
9/30/2017N/A-4N/A-17N/A
6/30/2017N/A-7N/A-18N/A
3/31/2017N/A-14N/A-16N/A
12/31/2016N/A-8N/A-19N/A
9/30/2016N/A-13N/A-15N/A
6/30/2016N/A-8N/A-17N/A
3/31/2016N/A-10N/A-18N/A
12/31/2015N/A-12N/A-14N/A
9/30/2015N/A-10N/A-13N/A
6/30/2015N/A-11N/A-10N/A
3/31/2015N/A-6N/A-5N/A
12/31/2014N/A-3N/A-4N/A
9/30/2014N/A-2N/A-2N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: EPIX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: EPIX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: EPIX is expected to become profitable in the next 3 years.

Revenue vs Market: EPIX is forecast to have no revenue next year.

High Growth Revenue: EPIX is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if EPIX's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/04 08:47
End of Day Share Price 2025/02/04 00:00
Earnings2024/09/30
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ESSA Pharma Inc. is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Maurice RaycroftJefferies LLC
Soumit RoyJonesTrading Institutional Services, LLC
Leland GershellOppenheimer & Co. Inc.